TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03096977

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scale for the assessment and rating of ataxia (SARA)
Description: Clinical evaluation of the manual dexterity through the SARA scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JAMAR hand dynamometer
Description: Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibratory sensibility testing
Description: Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sermes and Weinstein test
Description: Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weber test
Description: Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times.
Study: NCT04098497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile intervention
Description: The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments.
Study: NCT02162914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib/active
Description: Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regorafenib/placebo
Description: Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
Study: NCT00162552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline
Description: Patients with severe cirrhosis treated with Pentoxifylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients with severe cirrhosis treated with a placebo
Study: NCT03595137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sono with Device
Description: In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sono only
Description: In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
Study: NCT02486159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal plaster (Sanfujiu)
Description: The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
Study: NCT01280383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive neurally adjusted ventilatory assist
Description: non-invasive neurally adjusted ventilatory assist in critically ill patients
Study: NCT03101033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical epidural neuroplasty
Description: Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural compound betamethasone injection
Description: Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal epidural compound betamethasone injection
Description: steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural hyaluronidase injection
Description: Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
Study: NCT01530659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Non-penetrating sham procedure to mimic implant procedure in the other eye.
Study: NCT04957407

Intervention type: OTHER
Intervention: pepsinogen
Description: diagnostic value of pepsinogen for severe atrophy and gastric cancer

Intervention type: OTHER
Intervention: pepsinogen
Description: diagnostic value of pepsinogen for severe atrophy and gastric cancer
Study: NCT00014222

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: 40,000 IU

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 5 mg/kg/d - days 2-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 75, 600 and 830 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 75, 600 and 830 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 75, 600 and 830 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 60 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 60 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride
Description: 60 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 500mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2
Study: NCT02230423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal surgery
Study: NCT00372177

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fab-fragment of Anti-human CD4
Description: Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
Study: NCT01673295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX infusions
Description: RTX + Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care only
Study: NCT00418418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary bypass operation
Description: Coronary bypass operation is performed via sternotomy during cardiac arrest.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronary bypass operation
Description: Coronary bypass operation is performed via sternotomy during cardiac arrest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow aspiration (crista iliaca)
Description: The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow aspiration (crista iliaca)
Description: The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramyocardial mesenchymal stem cell transplantation
Description: During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intramyocardial injection of autologous serum
Description: Intramyocardial injection of autologous serum is injected during cardiac arrest
Study: NCT03430661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Tablet for oral administration (180 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Tablet for oral administration (180 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Tablet for oral administration (180 mg)
Study: NCT02707471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SM-AET
Description: self-management for improving adherence and reducing symptom interference (SM-AET)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: general health education
Description: general health education intervention that focuses on improving overall health.
Study: NCT02670382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: 10 week supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 10 week supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: 4-week lead-in
Study: NCT03040427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
Study: NCT05604794

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ketamine-Assisted Psychotherapy (KAP)
Description: KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
Study: NCT00923663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Lenalidomide p.o. daily for 21 days
Study: NCT03165474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based comic and newsletters
Description: Web-based comic and health messages (child component) and health newsletters (parent component)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic health information
Description: Didactic health information and resources by email and/or text
Study: NCT01833936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compex® muscle stimulator
Description: The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: (inactive) muscle stimulator
Description: A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
Study: NCT04453800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofadil【Neu2000KW】
Description: 500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofadil
Description: 750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofadil
Description: 1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline was administered intravenously
Study: NCT04390763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIS793
Description: anti-TGFb antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIS793
Description: anti-TGFb antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIS793
Description: anti-TGFb antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: anti-PD-1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: SOC chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: SOC chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: SOC chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: SOC chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: SOC chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: SOC chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: SOC chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: SOC chemotherapy
Study: NCT01685853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl plus PEG-CS
Description: * the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 4 litres split
Description: * the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination
Study: NCT00623597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 2.5-3.0mg/kg po bid (starting dose) for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 50mg/kg po bid (starting dose) for 48 weeks
Study: NCT03092245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OctaplasLG
Description: OctaplasLG is given as an infusion when resuscitation fluids are required.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer-Acetate
Description: Ringer-acetate is given as an infusion when resuscitation fluids are required.
Study: NCT01136798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
Study: NCT01820637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
Description: Drug-eluting SFA self-expanding stent
Study: NCT00583115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 260 mg/M2/day, given once daily by mouth
Study: NCT01713998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT04609410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade
Description: Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular blockade
Description: Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
Study: NCT01800578

Intervention type: DEVICE
Intervention: monitor for depth of hypnosis
Description: evaluation of depth of hypnosis~--------------------------------------------------------------------------------
Study: NCT04071093

Intervention type: OTHER
Group type: OTHER
Intervention: Home Telemonitoring System (HTS)
Description: The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
Study: NCT03811834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
Study: NCT01424176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (dose 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (dose 2)
Study: NCT00640042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate extended release capsules
Description: 30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
Study: NCT02631616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Monthly injections of Somatostatin
Study: NCT04043806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT02277587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenadren
Description: Oral Tablets: 20-25-30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glucocorticoid therapy
Description: Oral Tablets: 20-25-30- 37.5 mg
Study: NCT03521206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP+ programme
Description: Training program for nursing home staff.